Spots Global Cancer Trial Database for A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
Official Title: An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Advanced Melanoma With BRAF V600 Mutation
Study ID: NCT05114603
Conditions
Interventions
Study Description
Brief Summary: An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University Cancer Hospita, Peking, Beijing, China
Hunan cancer hospital, Changsha, , China
West China Hospital of Sichuan University, Chendu, , China
Fujian cancer hospital, Fujian, , China
Shangxi Bethune Hospita, Taiyuan, , China
union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, , China
Henan cancer hospital, Zhengzhou, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
